Landos Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Landos Biopharma

15/11/2021 14:32

* Landos Biopharma Inc  LABP.OQ  reported a quarterly adjusted
loss of 32 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 44 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Landos Biopharma Inc's reported EPS for the quarter was a loss
of 32 cents​.
* The mean earnings estimate of analysts had risen by about 5.2%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Landos Biopharma Inc shares had risen by 2.6% this quarter.
* The company reported a quarterly loss of $12.6 million.
* Wall Street's median 12-month price target for Landos
Biopharma Inc is $35.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 15 at 02:32 p.m.
 ​All figures in US dollars unless otherwise stated